| 研究 | 人群 | 干预 |
| 年龄(岁) |
| 性别男/女(n) |
| PEP (n) | ||||||||
| 组1 | 组2 | 组3 | 组1 | 组2 | 组3 | 组1 | 组2 | 组3 | 组1 | 组2 | 组3 | |||||
| Weiland 2021 | 中高 风险 | N100mg | N100mg + LR | \ | 60 (49 - 71) | 57 (44 - 71) |
| 175/250 | 156/232 |
| 39 | 30 |
| |||
| Hosseini 2016* | 平均 风险 | PLA | N100mg |
| 49 ± 14.26 50.76 ± 13.32 | 51.20 ± 12.12 47.91 ± 11.06 |
| 103/102 | 99/102 |
| 27 | 11 |
| |||
| Lai 2019 | 平均 风险 | N100mg | N高 剂量 |
| 60.5 ± 16.9 | 59.3 ± 15.7 |
| 47/28 | 54/33 |
| 3 | 6 |
| |||
| Andrade-Dávila 2015 | 高风险 | PLA | N100mg |
| 54.0 ± 17.85 | 51.59 ± 18.55 |
| 25/59 | 31/51 |
| 17 | 4 |
| |||
| Döbrönte 2014 | 平均 风险 | PLA | N100mg |
| 67.68 ± 15.56 | 65.66 ± 16.21 |
| 133/214 | 106/212 |
| 22 | 20 |
| |||
| UÇAR 2016 | 平均 风险 | PLA | N100mg |
| 60.5 ± 17.6 | 59 ± 18.6 |
| 20/30 | 13/37 |
| 7 | 1 |
| |||
| Kamal 2019 | 高风险 | N100mg | N100mg + SE |
| 52.1 ± 14.3 | 52.5 ± 15.6 |
| 201/276 | 207/275 |
| 31 | 32 |
| |||
| Wang 2020 | 高风险 | PLA | N100mg + TI |
| 63.5 ± 14.4 | 66.87 ± 13 |
| / | / |
| 34 | 9 |
| |||
| Romano-Munive 2021 | 平均 风险 | N100mg | N100mg + SE |
| 51.8 ± 20.3 | 50.3 ± 21.4 |
| 87/188 | 81/192 |
| 14 | 10 |
| |||
| Elmunzer 2012 | 高风险 | PLA | N100mg |
| 46.0 ± 13.1 | 44.4 ± 13.5 |
| 66/229 | 60/247 |
| 52 | 27 |
| |||
| Norouzi 2021 | 高风险 | N100mg | N100mg + S |
| 62.95 (15.58) | 63.03 (16.57) |
| 86/98 | 76/116 |
| 28 | 22 |
| |||
| Fogel 2019 | 高风险 | N100mg | N高 剂量 |
| 49∙3 (15∙2) | 50∙4 (15∙0) |
| 101/421 | 123/392 |
| 76 | 65 |
| |||
| Hatami 2018 | 平均 风险 | N100mg | N100mg + SE |
| 58.06 ± 17.13 | 59.62 ± 15.37 |
| 41/27 | 24/34 |
| 6 | 0 |
| |||
| Sotoudehmanesh 2007 | 平均 风险 | PLA | N100mg |
| 58.1 ± 16.8 | 58.4 ± 17.1 |
| 115/130 | 111/134 |
| 15 | 7 |
| |||
| Katsinelos 2012 | 平均 风险 | PLA | N100mg + S |
| 68.4 (14.7) | 69.2 (15.1) |
| 110/150 | 122/133 |
| 27 | 12 |
| |||
| Khoshbaten 2008 | 高风险 | PLA | N100mg |
| 57 ± 15 | 60 ± 17 |
| 25/25 | 22/28 |
| 13 | 2 |
| |||
| Loza 2007 | 平均 风险 | PLA | N100mg |
| 51.12 ±17 | 55.37 ± 18.0 |
| 24/51 | 26/49 |
| 12 | 4 |
| |||
| Lua 2015 | 中高 风险 | PLA | N100mg |
| 64.3 | 64.9 |
| 105/118 | 108/118 |
| 11 | 16 |
| |||
| Luo 2016 | 平均 风险 | PLA | N100mg |
| 63 (50 - 74) | 62 (50 - 72) |
| 619/684 | 618/679 |
| 100 | 47 |
| |||
| Luo 2019 | 平均 风险 | N100mg | N100mg + SE |
| 61 (49 - 71) | 62 (50 - 71) |
| 295/281 | 302/280 |
| 31 | 49 |
| |||
| Mok 2016 | 高风险 | PLA | N100mg | N100mg + LR | 58 | 62 | 63 | 19/29 | 15/33 | 25/23 | 10 | 6 | 3 | |||
| Patai 2015 | 平均 风险 | PLA | N100mg |
| 64.51 (20 - 95) | 66.25 (23 - 100) |
| 88/181 | 89/181 |
| 37 | 18 |
| |||
| Patil 2016 | 高风险 | PLA | N100mg |
| 47.86 | 45.44 |
| 72/128 | 77/123 |
| 23 | 6 |
| |||
| Masjedizadeh 2017 | 平均 风险 | PLA | N100mg |
| 56.25 | 57.97 |
| 28/34 | 24/38 |
| 20 | 16 |
| |||
| Sadeghi 2019 | 平均 风险 | N100mg | N100mg + M |
| 58.0 ± 16.8 | 60.1 ± 14.8 |
| 70/70 | 67/73 |
| 19 | 14 |
| |||
| Sotoudehmanesh 2014 | 平均 风险 | N100mg | N100mg + TI |
| 58.6 ± 17.5 | 58.4 ± 17.8 |
| 70/80 | 76/74 |
| 23 | 10 |
| |||
| Murray 2003 | 平均 风险 | PLA | N100mg |
| 58 ± 14 | 55 ± 15 |
| 36/74 | 41/69 |
| 17 | 7 |
| |||